|
1
|
Brodeur GM: Neuroblastoma: Biological
insights into a clinical enigma. Nat Rev Cancer. 3:203–216. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maris JM, Hogarty MD, Bagatell R and Cohn
SL: Neuroblastoma. Lancet. 369:2106–2120. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maris JM: Recent advances in
neuroblastoma. N Engl J Med. 362:2202–2211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hüsemann Y, Geigl JB, Schubert F, Musiani
P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G and
Klein CA: Systemic spread is an early step in breast cancer. Cancer
Cell. 13:58–68. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rhim AD, Mirek ET, Aiello NM, et al: EMT
and dissemination precede pancreatic tumor formation. Cell.
148:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kang Y and Pantel K: Tumor cell
dissemination: Emerging biological insights from animal models and
cancer patients. Cancer Cell. 23:573–581. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Müller V, Alix-Panabières C and Pantel K:
Insights into minimal residual disease in cancer patients:
Implications for anti-cancer therapies. Eur J Cancer. 46:1189–1197.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin H, Balic M, Zheng S, Datar R and Cote
RJ: Disseminated and circulating tumor cells: Role in effective
cancer management. Crit Rev Oncol Hematol. 77:1–11. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mordant P, Loriot Y, Lahon B, Castier Y,
Lesèche G, Soria JC, Massard C and Deutsch E: Minimal residual
disease in solid neoplasia: New frontier or red-herring? Cancer
Treat Rev. 38:101–110. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Viprey VF, Lastowska MA, Corrias MV,
Swerts K, Jackson MS and Burchill SA: Minimal disease monitoring by
QRT-PCR: guidelines for identification and systematic validation of
molecular markers prior to evaluation in prospective clinical
trials. J Pathol. 216:245–252. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cheung IY, Feng Y, Gerald W and Cheung NK:
Exploiting gene expression profiling to identify novel minimal
residual disease markers of neuroblastoma. Clin Cancer Res.
14:7020–7027. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stutterheim J, Gerritsen A,
Zappeij-Kannegieter L, Yalcin B, Dee R, van Noesel MM, Berthold F,
Versteeg R, Caron HN, van der Schoot CE and Tytgat GA: Detecting
minimal residual disease in neuroblastoma: The superiority of a
panel of real-time quantitative PCR markers. Clin Chem.
55:1316–1326. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hartomo TB, Kozaki A, Hasegawa D, Van
Huyen Pham T, Yamamoto N, Saitoh A, Ishida T, Kawasaki K, Kosaka Y,
Ohashi H, et al: Minimal residual disease monitoring in
neuroblastoma patients based on the expression of a set of
real-time RT-PCR markers in tumor-initiating cells. Oncol Rep.
29:1629–1636. 2013.PubMed/NCBI
|
|
14
|
Stutterheim J, Zappeij-Kannegieter L,
Versteeg R, Caron HN, van der Schoot CE and Tytgat GA: The
prognostic value of fast molecular response of marrow disease in
patients aged over 1 year with stage 4 neuroblastoma. Eur J Cancer.
47:1193–1202. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yáñez Y, Grau E, Oltra S, Cañete A,
Martínez F, Orellana C, Noguera R, Palanca S and Castel V: Minimal
disease detection in peripheral blood and bone marrow from patients
with non-metastatic neuroblastoma. J Cancer Res Clin Oncol.
137:1263–1272. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Corrias MV, Haupt R, Carlini B, Cappelli
E, Giardino S, Tripodi G, Tonini GP, Garaventa A, Pistoia V and
Pistorio A: Multiple target molecular monitoring of bone marrow and
peripheral blood samples from patients with localized neuroblastoma
and healthy donors. Pediatr Blood Cancer. 58:43–49. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Castleberry RP, Pritchard J, Ambros P,
Berthold F, Brodeur GM, Castel V, Cohn SL, De Bernardi B,
Dicks-Mireaux C, Frappaz D, et al: The international neuroblastoma
risk groups (INRG): a preliminary report. Eur J Cancer.
33:2113–2116. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stutterheim J, Zappeij-Kannegieter L, Ora
I, van Sluis PG, Bras J, den Ouden E, Versteeg R, Caron HN, van der
Schoot CE and Tytgat GA: Stability of PCR targets for monitoring
minimal residual disease in neuroblastoma. J Mol Diagn. 14:168–175.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vermeulen L, de Sousa e Melo F, Richel DJ
and Medema JP: The developing cancer stem-cell model: clinical
challenges and opportunities. Lancet Oncol. 13:e83–e89. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Plaks V, Koopman CD and Werb Z: Cancer:
Circulating tumor cells. Science. 341:1186–1188. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Alix-Panabières C and Pantel K: Challenges
in circulating tumour cell research. Nat Rev Cancer. 14:623–631.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Baccelli I, Schneeweiss A, Riethdorf S,
Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bäuerle T,
Wallwiener M, et al: Identification of a population of blood
circulating tumor cells from breast cancer patients that initiates
metastasis in a xenograft assay. Nat Biotechnol. 31:539–544. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hodgkinson CL, Morrow CJ, Li Y, Metcalf
RL, Rothwell DG, Trapani F, Polanski R, Burt DJ, Simpson KL, Morris
K, et al: Tumorigenicity and genetic profiling of circulating tumor
cells in small-cell lung cancer. Nat Med. 20:897–903. 2014.
View Article : Google Scholar : PubMed/NCBI
|
